Atezolizumab in the treatment of lung cancer

05/2021

MUDr. Leona Koubková

Pneumologická klinika 2. LF UK a FN v Motole, Praha

SUMMARY

Immuno-oncotherapy is already an integral part of lung cancer treatment. Especially in the first line treatment of non-small cell lung cancer (NSCLC) either in monotherapy of tumors with high expression of programmed cell death protein ligand 1 (PD-L1) or in combination with other treatment modalities leads to prolongation of overall survival and survival without progress. Atezolizumab, a monoclonal antibody against PD-L1, has been approved by the European Medicines Agency based on a number of studies to treat firstand higher-line NSCLC and as a first-line checkpoint inhibitor for first-line extensive small cell lung cancer.

Key words

non-small cell lung cancer, small cell lung cancer, immunotherapy, atezolizumab